EE05220B1 - Bis-arüülühend, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks - Google Patents
Bis-arüülühend, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseksInfo
- Publication number
- EE05220B1 EE05220B1 EEP200300225A EEP200300225A EE05220B1 EE 05220 B1 EE05220 B1 EE 05220B1 EE P200300225 A EEP200300225 A EE P200300225A EE P200300225 A EEP200300225 A EE P200300225A EE 05220 B1 EE05220 B1 EE 05220B1
- Authority
- EE
- Estonia
- Prior art keywords
- compound
- bis
- preparation
- pharmaceutical formulation
- formulation containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10060807A DE10060807A1 (de) | 2000-12-07 | 2000-12-07 | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| PCT/EP2001/013680 WO2002046162A1 (de) | 2000-12-07 | 2001-11-24 | Ortho-substituierte stickstoffhaltige bisarylverbindungen zur verwendung als kalium-kanal-inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200300225A EE200300225A (et) | 2003-08-15 |
| EE05220B1 true EE05220B1 (et) | 2009-10-15 |
Family
ID=7666129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300225A EE05220B1 (et) | 2000-12-07 | 2001-11-24 | Bis-arüülühend, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6794377B2 (hu) |
| EP (1) | EP1341764B1 (hu) |
| JP (1) | JP4445198B2 (hu) |
| KR (1) | KR100815070B1 (hu) |
| CN (1) | CN1237052C (hu) |
| AR (1) | AR033408A1 (hu) |
| AT (1) | ATE297897T1 (hu) |
| AU (2) | AU2189202A (hu) |
| BR (1) | BR0116005A (hu) |
| CA (1) | CA2436891C (hu) |
| CZ (1) | CZ301923B6 (hu) |
| DE (2) | DE10060807A1 (hu) |
| DK (1) | DK1341764T3 (hu) |
| EE (1) | EE05220B1 (hu) |
| ES (1) | ES2242792T3 (hu) |
| HK (1) | HK1066539A1 (hu) |
| HR (1) | HRP20030448B1 (hu) |
| HU (1) | HUP0302762A3 (hu) |
| IL (2) | IL156312A0 (hu) |
| MX (1) | MXPA03004966A (hu) |
| NO (1) | NO325297B1 (hu) |
| NZ (1) | NZ526294A (hu) |
| PL (1) | PL207057B1 (hu) |
| PT (1) | PT1341764E (hu) |
| RU (1) | RU2275360C2 (hu) |
| SI (1) | SI1341764T1 (hu) |
| SK (1) | SK286056B6 (hu) |
| TW (1) | TWI242005B (hu) |
| WO (1) | WO2002046162A1 (hu) |
| YU (1) | YU40203A (hu) |
| ZA (1) | ZA200303931B (hu) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| US7125898B2 (en) * | 2002-02-12 | 2006-10-24 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors. |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
| DE10341233A1 (de) * | 2003-09-08 | 2005-03-24 | Aventis Pharma Deutschland Gmbh | Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien |
| US20050054673A1 (en) * | 2003-09-08 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
| JP2008522978A (ja) * | 2004-12-07 | 2008-07-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | ３，６−ビシクロライド |
| US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| WO2007015775A2 (en) * | 2005-07-22 | 2007-02-08 | Merck & Co., Inc. | Potassium channel inhibitors |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| WO2007124849A2 (en) * | 2006-04-27 | 2007-11-08 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the task-1 and task-3 ion channel |
| GB0815782D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815781D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815784D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| EP2459541A1 (en) | 2009-07-30 | 2012-06-06 | F. Hoffmann-La Roche AG | Dihydropyrimidone amides as p2x7 modulators |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| NO3175985T3 (hu) | 2011-07-01 | 2018-04-28 | ||
| WO2013112932A1 (en) | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| WO2014183221A1 (en) * | 2013-05-17 | 2014-11-20 | The Centre For Drug Research And Development | Resveratrol analogs and therapeutic uses thereof |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| EP3558992A4 (en) | 2016-12-15 | 2020-12-02 | ONO Pharmaceutical Co., Ltd. | ACTIVATOR OF TREK (TWIK-ASSOCIATED K + CHANNELS) CHANNELS |
| UA128288C2 (uk) | 2018-03-08 | 2024-05-29 | Інсайт Корпорейшн | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4616002A (en) * | 1984-11-09 | 1986-10-07 | Ciba-Geigy Corporation | Dihydro pyridine compounds, compositions and use |
| US5196537A (en) * | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
| DE4430638A1 (de) * | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel |
| US5670504A (en) | 1995-02-23 | 1997-09-23 | Merck & Co. Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
| US6083986A (en) * | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| US5935945A (en) | 1996-10-31 | 1999-08-10 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| US5969017A (en) | 1996-10-31 | 1999-10-19 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
| CA2334258A1 (en) | 1998-06-05 | 1999-12-09 | Icagen, Inc. | Potassium channel inhibitors |
| EP1109544A4 (en) * | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE |
| DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
-
2000
- 2000-12-07 DE DE10060807A patent/DE10060807A1/de not_active Withdrawn
-
2001
- 2001-11-24 PL PL365318A patent/PL207057B1/pl not_active IP Right Cessation
- 2001-11-24 JP JP2002547901A patent/JP4445198B2/ja not_active Expired - Fee Related
- 2001-11-24 YU YU40203A patent/YU40203A/sh unknown
- 2001-11-24 AU AU2189202A patent/AU2189202A/xx active Pending
- 2001-11-24 CN CNB018201814A patent/CN1237052C/zh not_active Expired - Fee Related
- 2001-11-24 ES ES01999558T patent/ES2242792T3/es not_active Expired - Lifetime
- 2001-11-24 AU AU2002221892A patent/AU2002221892B2/en not_active Ceased
- 2001-11-24 SI SI200130385T patent/SI1341764T1/xx unknown
- 2001-11-24 WO PCT/EP2001/013680 patent/WO2002046162A1/de active IP Right Grant
- 2001-11-24 CA CA2436891A patent/CA2436891C/en not_active Expired - Fee Related
- 2001-11-24 SK SK687-2003A patent/SK286056B6/sk not_active IP Right Cessation
- 2001-11-24 DK DK01999558T patent/DK1341764T3/da active
- 2001-11-24 DE DE50106549T patent/DE50106549D1/de not_active Expired - Lifetime
- 2001-11-24 CZ CZ20031564A patent/CZ301923B6/cs not_active IP Right Cessation
- 2001-11-24 KR KR1020037007552A patent/KR100815070B1/ko not_active IP Right Cessation
- 2001-11-24 AT AT01999558T patent/ATE297897T1/de active
- 2001-11-24 RU RU2003120080/04A patent/RU2275360C2/ru not_active IP Right Cessation
- 2001-11-24 NZ NZ526294A patent/NZ526294A/en unknown
- 2001-11-24 EE EEP200300225A patent/EE05220B1/xx not_active IP Right Cessation
- 2001-11-24 HU HU0302762A patent/HUP0302762A3/hu unknown
- 2001-11-24 IL IL15631201A patent/IL156312A0/xx unknown
- 2001-11-24 BR BR0116005-2A patent/BR0116005A/pt not_active Application Discontinuation
- 2001-11-24 EP EP01999558A patent/EP1341764B1/de not_active Expired - Lifetime
- 2001-11-24 PT PT01999558T patent/PT1341764E/pt unknown
- 2001-11-24 MX MXPA03004966A patent/MXPA03004966A/es active IP Right Grant
- 2001-12-05 TW TW090130040A patent/TWI242005B/zh active
- 2001-12-05 AR ARP010105665A patent/AR033408A1/es active IP Right Grant
- 2001-12-05 US US10/002,326 patent/US6794377B2/en not_active Expired - Fee Related
-
2003
- 2003-05-21 ZA ZA200303931A patent/ZA200303931B/en unknown
- 2003-06-02 NO NO20032488A patent/NO325297B1/no not_active IP Right Cessation
- 2003-06-04 IL IL156312A patent/IL156312A/en not_active IP Right Cessation
- 2003-06-04 HR HR20030448A patent/HRP20030448B1/xx not_active IP Right Cessation
-
2004
- 2004-12-01 HK HK04109460A patent/HK1066539A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE05220B1 (et) | Bis-arüülühend, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks | |
| EE200300240A (et) | Arüülitud furaan- ja tiofeenkarboksamiid, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks | |
| DZ3313A1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
| IL136901A0 (en) | Flash-melt oral dosage formulation | |
| FR2804025B1 (fr) | Compositions pharmaceutiques stabilisees | |
| DZ3311A1 (fr) | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation | |
| HUP0204101A3 (en) | 3-aminoquinazolin-2,4-dione antibacterial agents, pharmaceutical compositions containing them and their use | |
| HUP0400636A3 (en) | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof | |
| HUP0700086A2 (en) | 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them | |
| EP1426027A4 (en) | COMPOSITION AND COSMETIC PREPARATION CONTAINING THE SAID COMPOSITION | |
| HUP0204514A3 (en) | Pyridinylimidazoles, pharmaceutical compositions containing them and their use | |
| AU9025701A (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same | |
| AU2001294808A1 (en) | Catecholamine pharmaceutical compositions and methods | |
| PL367180A1 (en) | Stabilized oral pharmaceutical composition | |
| MXPA03004941A (es) | Formulacion farmacologica que tiene tolerancia por via oral mejorada. | |
| MXPA02011722A (es) | Composicion y aplicador para suministro de sustancias topicas. | |
| HUP0301573A3 (en) | Substituted arylpyrazines, pharmaceutical compositions containing them and their use | |
| EE05475B1 (et) | Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon | |
| AU7645701A (en) | Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides | |
| HUP0400967A3 (en) | Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them | |
| EE200300398A (et) | Isoksasoliini derivaat, selle saamine ja kasutamine depresioonivastase ravimi valmistamiseks ning seda sisaldav ravimkompositsioon | |
| GB2368461B (en) | Formulation of multiple gate oxides thicknesses | |
| EE200200493A (et) | Lipiidne kandesüsteem, selle kasutamine ravimpreparaatide valmistamiseks ning seda sisaldav farmatseutiline kompositsioon | |
| EE05406B1 (et) | Memnopeptiidhend, selle valmistamine ja kasutamine ning seda sisaldav farmatseutiline kompositsioon | |
| FR2831440B1 (fr) | Composition cosmetique, renfermant un derive de la dhea et un agent apaisant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20111124 |